Status:
COMPLETED
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Neoplasm Metastasis
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer ...
Eligibility Criteria
Inclusion
- Stage IIIB, IIIC or IV breast cancer not curable with available therapy.
- Patients must have progressed after 1 but not more than 3 prior chemotherapy regimens.
- Life expectancy of at least 16 weeks.
- Ability to swallow whole capsules.
Exclusion
- Use of or requirement for bisphosphonates within 8 weeks prior to screening.
- Any other cancer within 5 years of screening, except for basal cell carcinoma or cervical carcinoma in situ
- Uncontrolled cardiac disease including congestive heart failure, angina, heart attack, etc.
- Recent or ongoing significant gastrointestinal disorder
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00319254
Start Date
May 1 2006
End Date
February 1 2009
Last Update
January 31 2013
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Duarte, California, United States, 91010-3000
2
Pfizer Investigational Site
Santa Monica, California, United States, 90404
3
Pfizer Investigational Site
Tampa, Florida, United States, 33612
4
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195